Publication | Closed Access

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

OncologyColorectal CancerPathologyRamucirumab Versus PlaceboPharmacotherapyCancer TreatmentMedicineRadiation OncologyPhase 3Second-line Folfiri